

## References

### I-21

1. Trastuzumab (Herceptin®) for injection, for intravenous use [package insert]. Genentech, Inc. South San Francisco, CA. Revised 11/2018.
2. Tse Hui L, Soon Tiong Lim A, Aye Aye T, et al. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer. *Archives of Pathology & Laboratory Medicine*. 2016;140(2):140-147.
3. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: breast cancer, version 2016.
4. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: esophageal and esophagogastric junction cancers, version 2015.
5. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: nonsmall cell lung cancer, version 2016.
6. Rugo H, Barve A, Pennella E, et al. Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical *JAMA*. 2017;317(1):37-47.
7. Denduluri N, Somerfield M, Wolff Selection of Optimal Adjuvant Chemotherapy Regimens for Early Breast Cancer and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline Summary. *Journal Of Oncology Practice*. May 2016;12(5):485-488.
8. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: breast cancer, version 2017.
9. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: esophageal and esophagogastric junction cancers, version 2017.

10. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: nonsmall cell lung cancer, version 2017.